Overview

12 / 48 Week Pivotal PFT vs PBO in COPD I

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD). The safety of BI 1744 CL inhalation solution delivered through the Respimat inhaler will also be compared to placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Olodaterol